ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

NASDAQ:ACRV • US0048901096

1.61 USD
+0.02 (+1.26%)
Last: Feb 19, 2026, 11:03 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ACRV gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. ACRV has a great financial health rating, but its profitability evaluates not so good. ACRV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ACRV has reported negative net income.
  • In the past year ACRV has reported a negative cash flow from operations.
  • ACRV had negative earnings in each of the past 5 years.
  • In the past 5 years ACRV always reported negative operating cash flow.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • ACRV has a Return On Assets of -56.26%. This is comparable to the rest of the industry: ACRV outperforms 44.72% of its industry peers.
  • Looking at the Return On Equity, with a value of -63.57%, ACRV is in line with its industry, outperforming 59.69% of the companies in the same industry.
Industry RankSector Rank
ROA -56.26%
ROE -63.57%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ACRV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ACRV has more shares outstanding
  • ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • ACRV has an Altman-Z score of -1.73. This is a bad value and indicates that ACRV is not financially healthy and even has some risk of bankruptcy.
  • ACRV's Altman-Z score of -1.73 is in line compared to the rest of the industry. ACRV outperforms 52.98% of its industry peers.
  • There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.73
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • ACRV has a Current Ratio of 8.75. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
  • ACRV has a Current ratio of 8.75. This is in the better half of the industry: ACRV outperforms 77.74% of its industry peers.
  • A Quick Ratio of 8.75 indicates that ACRV has no problem at all paying its short term obligations.
  • ACRV's Quick ratio of 8.75 is fine compared to the rest of the industry. ACRV outperforms 77.74% of its industry peers.
Industry RankSector Rank
Current Ratio 8.75
Quick Ratio 8.75
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ACRV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.11%, which is quite impressive.
EPS 1Y (TTM)21.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ACRV will show a small growth in Earnings Per Share. The EPS will grow by 6.33% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.05%
EPS Next 2Y9.78%
EPS Next 3Y5.3%
EPS Next 5Y6.33%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ACRV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACRV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.78%
EPS Next 3Y5.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ACRV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (2/19/2026, 11:03:44 AM)

1.61

+0.02 (+1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-24
Inst Owners56.12%
Inst Owner Change1.7%
Ins Owners8.19%
Ins Owner Change-0.49%
Market Cap50.81M
Revenue(TTM)N/A
Net Income(TTM)-81.75M
Analysts82.67
Price Target11.73 (628.57%)
Short Float %8.08%
Short Ratio1.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.96%
Min EPS beat(2)8.02%
Max EPS beat(2)21.9%
EPS beat(4)4
Avg EPS beat(4)16%
Min EPS beat(4)8.02%
Max EPS beat(4)22.15%
EPS beat(8)6
Avg EPS beat(8)9.81%
EPS beat(12)10
Avg EPS beat(12)10.46%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.98%
PT rev (3m)2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.19%
EPS NY rev (1m)0.64%
EPS NY rev (3m)9.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)14.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.4
P/tB 0.4
EV/EBITDA N/A
EPS(TTM)-2.13
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-2.08
OCFYN/A
SpS0
BVpS4.07
TBVpS4.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.26%
ROE -63.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 175.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.75
Quick Ratio 8.75
Altman-Z -1.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.34%
EPS Next Y16.05%
EPS Next 2Y9.78%
EPS Next 3Y5.3%
EPS Next 5Y6.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.96%
OCF growth 3YN/A
OCF growth 5YN/A

ACRIVON THERAPEUTICS INC / ACRV FAQ

Can you provide the ChartMill fundamental rating for ACRIVON THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACRV.


What is the valuation status of ACRIVON THERAPEUTICS INC (ACRV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACRIVON THERAPEUTICS INC (ACRV). This can be considered as Overvalued.


Can you provide the profitability details for ACRIVON THERAPEUTICS INC?

ACRIVON THERAPEUTICS INC (ACRV) has a profitability rating of 1 / 10.


How financially healthy is ACRIVON THERAPEUTICS INC?

The financial health rating of ACRIVON THERAPEUTICS INC (ACRV) is 7 / 10.